-
1
-
-
0033774195
-
Adjuvant therapy in melanoma
-
Whittaker S: Adjuvant therapy in melanoma. Clin Exp Dermatol 2000;25:497-502.
-
(2000)
Clin Exp Dermatol
, vol.25
, pp. 497-502
-
-
Whittaker, S.1
-
2
-
-
0031806982
-
Chemoresistance of human malignant melanoma: Cellular and molecular aspects
-
Berger W, Elbling L, Micksche M: Chemoresistance of human malignant melanoma: Cellular and molecular aspects. Onkologie 1998;21:105-110.
-
(1998)
Onkologie
, vol.21
, pp. 105-110
-
-
Berger, W.1
Elbling, L.2
Micksche, M.3
-
4
-
-
0033910314
-
Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease
-
Walsh P, Gibbs P, Gonzalez R: Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease. J Am Acad Dermatol 2000;42:480-489.
-
(2000)
J Am Acad Dermatol
, vol.42
, pp. 480-489
-
-
Walsh, P.1
Gibbs, P.2
Gonzalez, R.3
-
6
-
-
0027218689
-
Biochemistry of multidrug resistance mediated by the multidrug transporter
-
Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
-
(1993)
Annu Rev Biochem
, vol.62
, pp. 385-427
-
-
Gottesman, M.M.1
Pastan, I.2
-
7
-
-
0031043119
-
The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance
-
Kavallaris M: The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anticancer Drugs 1997;8:17-25.
-
(1997)
Anticancer Drugs
, vol.8
, pp. 17-25
-
-
Kavallaris, M.1
-
8
-
-
0035253361
-
Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group Study
-
Gaynor ER, Unger JM, Miller TP, Grogan TM, White LA Jr., Mills GM, Balcerzak SP, Varterasian M, LeBlanc M, Fisher RI: Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group Study. J Clin Oncol 2001;19:750-755.
-
(2001)
J Clin Oncol
, vol.19
, pp. 750-755
-
-
Gaynor, E.R.1
Unger, J.M.2
Miller, T.P.3
Grogan, T.M.4
White Jr., L.A.5
Mills, G.M.6
Balcerzak, S.P.7
Varterasian, M.8
LeBlanc, M.9
Fisher, R.I.10
-
9
-
-
0035760302
-
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study
-
List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, Dorr R, Karanes C, Hynes HE, Doroshow JH, Shurafa M, Appelbaum FR: Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 2001;98:3212-3220.
-
(2001)
Blood
, vol.98
, pp. 3212-3220
-
-
List, A.F.1
Kopecky, K.J.2
Willman, C.L.3
Head, D.R.4
Persons, D.L.5
Slovak, M.L.6
Dorr, R.7
Karanes, C.8
Hynes, H.E.9
Doroshow, J.H.10
Shurafa, M.11
Appelbaum, F.R.12
-
10
-
-
0028965334
-
P-glycoprotein expression in primary and metastatic malignant melanoma
-
Schadendorf D, Herfordt R, Czarnetzki BM: P-glycoprotein expression in primary and metastatic malignant melanoma. Br J Dermatol 1995;132:551-555.
-
(1995)
Br J Dermatol
, vol.132
, pp. 551-555
-
-
Schadendorf, D.1
Herfordt, R.2
Czarnetzki, B.M.3
-
11
-
-
0344927562
-
Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity, and MRP2-mediated drug resistance
-
Konig J, Nies AT, Cui Y, Leier I, Keppler D: Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1999;1461:377-394.
-
(1999)
Biochim Biophys Acta
, vol.1461
, pp. 377-394
-
-
Konig, J.1
Nies, A.T.2
Cui, Y.3
Leier, I.4
Keppler, D.5
-
12
-
-
0028851632
-
Membrane transport proteins associated with drug resistance expressed in human melanoma
-
Schadendorf D, Makki A, Stahr C, van Dyck A, Wanner R, Scheffer GL, Flens MJ, Scheper R, Henz BM: Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol 1995;147:1545-1552.
-
(1995)
Am J Pathol
, vol.147
, pp. 1545-1552
-
-
Schadendorf, D.1
Makki, A.2
Stahr, C.3
Van Dyck, A.4
Wanner, R.5
Scheffer, G.L.6
Flens, M.J.7
Scheper, R.8
Henz, B.M.9
-
13
-
-
0030932462
-
Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells
-
Berger W, Hauptmann E, Elbling L, Vetterlein M, Kokoschka EM, Micksche M: Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells. Int J Cancer 1997;71:108-115.
-
(1997)
Int J Cancer
, vol.71
, pp. 108-115
-
-
Berger, W.1
Hauptmann, E.2
Elbling, L.3
Vetterlein, M.4
Kokoschka, E.M.5
Micksche, M.6
-
14
-
-
0035030272
-
Chemotherapy induces or increases expression of multidrug resistance-associated protein in malignant melanoma cells
-
Ichihashi N, Kitajima Y: Chemotherapy induces or increases expression of multidrug resistance-associated protein in malignant melanoma cells. Br J Dermatol 2001;144:745-750.
-
(2001)
Br J Dermatol
, vol.144
, pp. 745-750
-
-
Ichihashi, N.1
Kitajima, Y.2
-
15
-
-
0041342087
-
Overexpression of cMOAT (MRP2/ABC2) is associated with decreased formation of platinium-DNA adducts, decreased G2-arrest, and decreased apoptotic activities in melanoma cells resistant to cisplatin
-
Materna V, Liedert B, Schadendorf D, Lage H: Overexpression of cMOAT (MRP2/ABC2) is associated with decreased formation of platinium-DNA adducts, decreased G2-arrest, and decreased apoptotic activities in melanoma cells resistant to cisplatin. J Invest Dermatol 2003;121:172-176.
-
(2003)
J Invest Dermatol
, vol.121
, pp. 172-176
-
-
Materna, V.1
Liedert, B.2
Schadendorf, D.3
Lage, H.4
-
16
-
-
0031939392
-
Glutathione-related mechanisms in cellular resistance to anticancer drugs
-
Zhang K, Mack P, Wong KP: Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol 1998;12:871-882.
-
(1998)
Int J Oncol
, vol.12
, pp. 871-882
-
-
Zhang, K.1
Mack, P.2
Wong, K.P.3
-
17
-
-
0037113935
-
Glutathione influences c-Myc-induced apoptosis in M14 human melanoma cells
-
Biroccio A, Benassi B, Filomeni G, Amodei S, Marchini S, Chiorino G, Rotilio G, Zupi G, Ciriolo MR: Glutathione influences c-Myc-induced apoptosis in M14 human melanoma cells. J Biol Chem 2002;277:43763-43770.
-
(2002)
J Biol Chem
, vol.277
, pp. 43763-43770
-
-
Biroccio, A.1
Benassi, B.2
Filomeni, G.3
Amodei, S.4
Marchini, S.5
Chiorino, G.6
Rotilio, G.7
Zupi, G.8
Ciriolo, M.R.9
-
19
-
-
0037565704
-
Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma
-
Wolchok JD, Williams L, Pinto JT, Fleisher M, Krown SE, Hwu WJ, Livingston PO, Chang C, Chapman PB: Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Res 2003;13:189-196.
-
(2003)
Melanoma Res
, vol.13
, pp. 189-196
-
-
Wolchok, J.D.1
Williams, L.2
Pinto, J.T.3
Fleisher, M.4
Krown, S.E.5
Hwu, W.J.6
Livingston, P.O.7
Chang, C.8
Chapman, P.B.9
-
20
-
-
0029553541
-
Acquisition of multiple copies of a mutant topoisomerase II alpha allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines
-
Campain JA, Slovak ML, Schoenlein PV, Popescu NC, Gottesman MM, Pastan I: Acquisition of multiple copies of a mutant topoisomerase II alpha allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines. Somat Cell Mol Genet 1995;21:451-471.
-
(1995)
Somat Cell Mol Genet
, vol.21
, pp. 451-471
-
-
Campain, J.A.1
Slovak, M.L.2
Schoenlein, P.V.3
Popescu, N.C.4
Gottesman, M.M.5
Pastan, I.6
-
21
-
-
0033957570
-
Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance
-
Lage H, Helmbach H, Dietel M, Schadendorf D: Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer 2000;82:488-491.
-
(2000)
Br J Cancer
, vol.82
, pp. 488-491
-
-
Lage, H.1
Helmbach, H.2
Dietel, M.3
Schadendorf, D.4
-
22
-
-
0033776290
-
Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma
-
Satherley K, de Souza L, Neale MH, Alexander RA, Myatt N, Foss AJ, Hungerford JL, Hickson ID, Cree IA: Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma. J Pathol 2000;192:174-181.
-
(2000)
J Pathol
, vol.192
, pp. 174-181
-
-
Satherley, K.1
De Souza, L.2
Neale, M.H.3
Alexander, R.A.4
Myatt, N.5
Foss, A.J.6
Hungerford, J.L.7
Hickson, I.D.8
Cree, I.A.9
-
23
-
-
0032922717
-
Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance
-
Lage H, Christmann M, Kern MA, Dietel M, Pick M, Kaina B, Schadendorf D: Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Int J Cancer 1999;80:744-750.
-
(1999)
Int J Cancer
, vol.80
, pp. 744-750
-
-
Lage, H.1
Christmann, M.2
Kern, M.A.3
Dietel, M.4
Pick, M.5
Kaina, B.6
Schadendorf, D.7
-
24
-
-
0034075593
-
Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide
-
Ruenger TM, Emmert S, Schadendorf D, Diem C, Epe B, Hellfritsch D: Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. J Invest Dermatol 2000;114:34-39.
-
(2000)
J Invest Dermatol
, vol.114
, pp. 34-39
-
-
Ruenger, T.M.1
Emmert, S.2
Schadendorf, D.3
Diem, C.4
Epe, B.5
Hellfritsch, D.6
-
25
-
-
0035313980
-
Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT
-
Christmann M, Pick M, Lage H, Schadendorf D, Kaina B: Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer 2001;92:123-129.
-
(2001)
Int J Cancer
, vol.92
, pp. 123-129
-
-
Christmann, M.1
Pick, M.2
Lage, H.3
Schadendorf, D.4
Kaina, B.5
-
26
-
-
0031597371
-
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma
-
Middleton MR, Lunn JM, Morris C, Rustin G, Wedge SR, Brampton MH, Lind MJ, Lee SM, Newell DR, Bleehen NM, Newlands ES, Calvert AH, Margison GP, Thatcher N: O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998;78:1199-1202.
-
(1998)
Br J Cancer
, vol.78
, pp. 1199-1202
-
-
Middleton, M.R.1
Lunn, J.M.2
Morris, C.3
Rustin, G.4
Wedge, S.R.5
Brampton, M.H.6
Lind, M.J.7
Lee, S.M.8
Newell, D.R.9
Bleehen, N.M.10
Newlands, E.S.11
Calvert, A.H.12
Margison, G.P.13
Thatcher, N.14
-
27
-
-
0033989205
-
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
-
Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-166.
-
(2000)
J Clin Oncol
, vol.18
, pp. 158-166
-
-
Middleton, M.R.1
Grob, J.J.2
Aaronson, N.3
Fierlbeck, G.4
Tilgen, W.5
Seiter, S.6
Gore, M.7
Aamdal, S.8
Cebon, J.9
Coates, A.10
Dreno, B.11
Henz, M.12
Schadendorf, D.13
Kapp, A.14
Weiss, J.15
Fraass, U.16
Statkevich, P.17
Muller, M.18
Thatcher, N.19
-
28
-
-
0036726694
-
Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy
-
Ma S, Egyhazi S, Ringborg U, Hansson J: Immunohistochemical analysis of DNA mismatch repair protein and O6-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy. Oncol Rep 2002;9:1015-1019.
-
(2002)
Oncol Rep
, vol.9
, pp. 1015-1019
-
-
Ma, S.1
Egyhazi, S.2
Ringborg, U.3
Hansson, J.4
-
29
-
-
0034630167
-
Induction of apoptosis by cancer chemotherapy
-
Kaufmann SH, Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256:42-49.
-
(2000)
Exp Cell Res
, vol.256
, pp. 42-49
-
-
Kaufmann, S.H.1
Earnshaw, W.C.2
-
30
-
-
0028960205
-
Tumor type is a determinant of susceptibility to apoptosis
-
Staunton MJ, Gaffney EF: Tumor type is a determinant of susceptibility to apoptosis. Am J Clin Pathol 1995;103:300-307.
-
(1995)
Am J Clin Pathol
, vol.103
, pp. 300-307
-
-
Staunton, M.J.1
Gaffney, E.F.2
-
31
-
-
0032536771
-
Two CD95 (APO-1/Fas) signaling pathways
-
Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME: Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998;17:1675-1687.
-
(1998)
EMBO J
, vol.17
, pp. 1675-1687
-
-
Scaffidi, C.1
Fulda, S.2
Srinivasan, A.3
Friesen, C.4
Li, F.5
Tomaselli, K.J.6
Debatin, K.M.7
Krammer, P.H.8
Peter, M.E.9
-
32
-
-
0030745646
-
Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3
-
Zou H, Henzel WJ, Liu X, Lutschg A, Wang X: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997;90:405-413.
-
(1997)
Cell
, vol.90
, pp. 405-413
-
-
Zou, H.1
Henzel, W.J.2
Liu, X.3
Lutschg, A.4
Wang, X.5
-
33
-
-
0030715323
-
Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
-
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-489.
-
(1997)
Cell
, vol.91
, pp. 479-489
-
-
Li, P.1
Nijhawan, D.2
Budihardjo, I.3
Srinivasula, S.M.4
Ahmad, M.5
Alnemri, E.S.6
Wang, X.7
-
34
-
-
0033596980
-
An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9
-
Zou H, Li Y, Liu X, Wang X: An APAF-1 cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999;274:11549-11556.
-
(1999)
J Biol Chem
, vol.274
, pp. 11549-11556
-
-
Zou, H.1
Li, Y.2
Liu, X.3
Wang, X.4
-
35
-
-
0030916417
-
DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis
-
Liu X, Zou H, Slaughter C, Wang X: DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 1997;89:175-184.
-
(1997)
Cell
, vol.89
, pp. 175-184
-
-
Liu, X.1
Zou, H.2
Slaughter, C.3
Wang, X.4
-
36
-
-
0032078217
-
Caspases: Key mediators of apoptosis
-
Thornberry NA: Caspases: Key mediators of apoptosis. Chem Biol 1998;5:R97-R103.
-
(1998)
Chem Biol
, vol.5
-
-
Thornberry, N.A.1
-
37
-
-
0036275357
-
Drug-resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency
-
Helmbach H, Kern MA, Rossmann E, Renz K, Kissel C, Gschwendt B, Schadendorf D: Drug-resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J Invest Dermatol 2002;118:923-932.
-
(2002)
J Invest Dermatol
, vol.118
, pp. 923-932
-
-
Helmbach, H.1
Kern, M.A.2
Rossmann, E.3
Renz, K.4
Kissel, C.5
Gschwendt, B.6
Schadendorf, D.7
-
38
-
-
0031825046
-
Drug resistance in ovarian cancer - The role of p53
-
Petty R, Evans A, Duncan I, Kurbacher C, Cree I: Drug resistance in ovarian cancer - the role of p53. Pathol Oncol Res 1998;4:97-102.
-
(1998)
Pathol Oncol Res
, vol.4
, pp. 97-102
-
-
Petty, R.1
Evans, A.2
Duncan, I.3
Kurbacher, C.4
Cree, I.5
-
39
-
-
0031812996
-
Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer
-
Miyake H, Hara I, Gohji K, Yamanaka K, Arakawa S, Kamidono S: Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer. Anticancer Res 1998;18:3087-3092.
-
(1998)
Anticancer Res
, vol.18
, pp. 3087-3092
-
-
Miyake, H.1
Hara, I.2
Gohji, K.3
Yamanaka, K.4
Arakawa, S.5
Kamidono, S.6
-
40
-
-
0029810981
-
Overexpression and mutations of p53 in metastatic malignant melanomas
-
Hartmann A, Blaszyk H, Cunningham JS, McGovern RM, Schroeder JS, Helander SD, Pittelkow MR, Sommer SS, Kovach JS: Overexpression and mutations of p53 in metastatic malignant melanomas. Int J Cancer 1996;67:313-317.
-
(1996)
Int J Cancer
, vol.67
, pp. 313-317
-
-
Hartmann, A.1
Blaszyk, H.2
Cunningham, J.S.3
McGovern, R.M.4
Schroeder, J.S.5
Helander, S.D.6
Pittelkow, M.R.7
Sommer, S.S.8
Kovach, J.S.9
-
41
-
-
0034125805
-
p53-dependent apoptosis in melanoma cells after treatment with camptothecin
-
Li G, Bush JA, Ho VC: p53-dependent apoptosis in melanoma cells after treatment with camptothecin. J Invest Dermatol 2000;114:514-519.
-
(2000)
J Invest Dermatol
, vol.114
, pp. 514-519
-
-
Li, G.1
Bush, J.A.2
Ho, V.C.3
-
42
-
-
0032944017
-
The chemoresistance of human malignant melanoma: An update
-
Serrone L, Hersey P: The chemoresistance of human malignant melanoma: An update. Melanoma Res 1999;9:51-58.
-
(1999)
Melanoma Res
, vol.9
, pp. 51-58
-
-
Serrone, L.1
Hersey, P.2
-
43
-
-
0032838899
-
Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice
-
Borner C, Schlagbauer Wadl H, Fellay I, Selzer E, Polterauer P, Jansen B: Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice. Melanoma Res 1999;9:347-350.
-
(1999)
Melanoma Res
, vol.9
, pp. 347-350
-
-
Borner, C.1
Schlagbauer Wadl, H.2
Fellay, I.3
Selzer, E.4
Polterauer, P.5
Jansen, B.6
-
44
-
-
0036379395
-
Regulation of Fas-mediated apoptosis by N-ras in melanoma
-
Urquhart JL, Meech SJ, Marr DG, Shellman YG, Duke RC, Norris DA: Regulation of Fas-mediated apoptosis by N-ras in melanoma. J Invest Dermatol 2002;119:556-561.
-
(2002)
J Invest Dermatol
, vol.119
, pp. 556-561
-
-
Urquhart, J.L.1
Meech, S.J.2
Marr, D.G.3
Shellman, Y.G.4
Duke, R.C.5
Norris, D.A.6
-
45
-
-
0031059608
-
Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis
-
Jansen B, Schlagbauer Wadl H, Eichler HG, Wolff K, van Elsas A, Schrier PI, Pehamberger H: Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. Cancer Res 1997;57:362-365.
-
(1997)
Cancer Res
, vol.57
, pp. 362-365
-
-
Jansen, B.1
Schlagbauer Wadl, H.2
Eichler, H.G.3
Wolff, K.4
Van Elsas, A.5
Schrier, P.I.6
Pehamberger, H.7
-
46
-
-
0036533441
-
Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects
-
Smalley KS, Eisen TG: Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. Int J Cancer 2002;98:514-522.
-
(2002)
Int J Cancer
, vol.98
, pp. 514-522
-
-
Smalley, K.S.1
Eisen, T.G.2
-
48
-
-
0000293602
-
Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma
-
Shin MS, Park WS, Kim SY, Kim HS, Kang SJ, Song KY, Park JY, Dong SM, Pi JH, Oh RR, Lee JY, Yoo NJ, Lee SH: Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol 1999;154:1785-1791.
-
(1999)
Am J Pathol
, vol.154
, pp. 1785-1791
-
-
Shin, M.S.1
Park, W.S.2
Kim, S.Y.3
Kim, H.S.4
Kang, S.J.5
Song, K.Y.6
Park, J.Y.7
Dong, S.M.8
Pi, J.H.9
Oh, R.R.10
Lee, J.Y.11
Yoo, N.J.12
Lee, S.H.13
-
49
-
-
0033609672
-
Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma
-
Ugurel S, Seiter S, Rappl G, Stark A, Tilgen W, Reinhold U: Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma. Int J Cancer 1999;82:727-736.
-
(1999)
Int J Cancer
, vol.82
, pp. 727-736
-
-
Ugurel, S.1
Seiter, S.2
Rappl, G.3
Stark, A.4
Tilgen, W.5
Reinhold, U.6
-
50
-
-
0033778257
-
Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma
-
Mouawad R, Khayat D, Soubrane C: Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma. Melanoma Res 2000;10:461-467.
-
(2000)
Melanoma Res
, vol.10
, pp. 461-467
-
-
Mouawad, R.1
Khayat, D.2
Soubrane, C.3
-
51
-
-
0032530612
-
Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells
-
Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998;161:2833-2840.
-
(1998)
J Immunol
, vol.161
, pp. 2833-2840
-
-
Griffith, T.S.1
Chin, W.A.2
Jackson, G.C.3
Lynch, D.H.4
Kubin, M.Z.5
-
52
-
-
0035523826
-
How melanoma cells evade trail-induced apoptosis
-
Hersey P, Zhang XD: How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 2001;1:142-150.
-
(2001)
Nat Rev Cancer
, vol.1
, pp. 142-150
-
-
Hersey, P.1
Zhang, X.D.2
-
53
-
-
0034283942
-
Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/apo-2 ligand gene induces tumor cell apoptosis
-
Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL: Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000;165:2886-2894.
-
(2000)
J Immunol
, vol.165
, pp. 2886-2894
-
-
Griffith, T.S.1
Anderson, R.D.2
Davidson, B.L.3
Williams, R.D.4
Ratliff, T.L.5
-
54
-
-
0035340285
-
The role of nf-kappab in tnf-related apoptosis-inducing ligand (trail)-induced apoptosis of melanoma cells
-
Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY, Thomas WD, Nguyen T, Hersey P: The role of nf-kappab in tnf-related apoptosis-inducing ligand (trail)-induced apoptosis of melanoma cells. J Immunol 2001;166:5337-5345.
-
(2001)
J Immunol
, vol.166
, pp. 5337-5345
-
-
Franco, A.V.1
Zhang, X.D.2
Van Berkel, E.3
Sanders, J.E.4
Zhang, X.Y.5
Thomas, W.D.6
Nguyen, T.7
Hersey, P.8
-
55
-
-
0033529266
-
Postmitochondrial regulation of apoptosis during heart failure
-
Reed JC, Paternostro G: Postmitochondrial regulation of apoptosis during heart failure. Proc Natl Acad Sci U S A 1999;96:7614-7616.
-
(1999)
Proc Natl Acad Sci U S A
, vol.96
, pp. 7614-7616
-
-
Reed, J.C.1
Paternostro, G.2
-
56
-
-
0035720233
-
The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis
-
Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, Sturm I, Daniel PT, Orfanos CE, Geilen CC: The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 2001;117:333-340.
-
(2001)
J Invest Dermatol
, vol.117
, pp. 333-340
-
-
Raisova, M.1
Hossini, A.M.2
Eberle, J.3
Riebeling, C.4
Wieder, T.5
Sturm, I.6
Daniel, P.T.7
Orfanos, C.E.8
Geilen, C.C.9
-
57
-
-
0036719158
-
Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity
-
Iervolino A, Trisciuoglio D, Ribatti D, Candiloro A, Biroccio A, Zupi G, Del Bufalo D: Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J 2002;16:1453-1455.
-
(2002)
FASEB J
, vol.16
, pp. 1453-1455
-
-
Iervolino, A.1
Trisciuoglio, D.2
Ribatti, D.3
Candiloro, A.4
Biroccio, A.5
Zupi, G.6
Del Bufalo, D.7
-
58
-
-
0034948497
-
c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells
-
Biroccio A, Benassi B, Amodei S, Gabellini C, Del Bufalo D, Zupi G: c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells. Mol Pharmacol 2001;60:174-182.
-
(2001)
Mol Pharmacol
, vol.60
, pp. 174-182
-
-
Biroccio, A.1
Benassi, B.2
Amodei, S.3
Gabellini, C.4
Del Bufalo, D.5
Zupi, G.6
-
59
-
-
0031907428
-
bcl-2 antisense therapy chemosensitizes human melanoma in Scid mice
-
Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG, Pehamberger H: bcl-2 antisense therapy chemosensitizes human melanoma in Scid mice. Nat Med 1998;4:232-234.
-
(1998)
Nat Med
, vol.4
, pp. 232-234
-
-
Jansen, B.1
Schlagbauer-Wadl, H.2
Brown, B.D.3
Bryan, R.N.4
Van Elsas, A.5
Muller, M.6
Wolff, K.7
Eichler, H.G.8
Pehamberger, H.9
-
60
-
-
0036568524
-
Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy
-
Heere-Ress E, Thallinger C, Lucas T, Schlagbauer-Wadl H, Wacheck V, Monia BP, Wolff K, Pehamberger H, Jansen B: Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer 2002;99:29-34.
-
(2002)
Int J Cancer
, vol.99
, pp. 29-34
-
-
Heere-Ress, E.1
Thallinger, C.2
Lucas, T.3
Schlagbauer-Wadl, H.4
Wacheck, V.5
Monia, B.P.6
Wolff, K.7
Pehamberger, H.8
Jansen, B.9
-
61
-
-
0036121142
-
Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages
-
Olie RA, Hafner C, Kuttel R, Sigrist B, Willers J, Dummer R, Hall J, Stahel RA, Zangemeister-Wittke U: Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J Invest Dermatol 2002;118:505-512.
-
(2002)
J Invest Dermatol
, vol.118
, pp. 505-512
-
-
Olie, R.A.1
Hafner, C.2
Kuttel, R.3
Sigrist, B.4
Willers, J.5
Dummer, R.6
Hall, J.7
Stahel, R.A.8
Zangemeister-Wittke, U.9
-
62
-
-
0002312941
-
Bcl-2 antisense plus dacarbacine therapy for malignan melanoma
-
Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Trevor L, Pratscher B, Hoermann M, Hollenstein U, Eichler H, Saunders RL, Fingert H, Wolff K, Pehamberger H: Bcl-2 antisense plus dacarbacine therapy for malignan melanoma. Proc Am Ass Cancer Res Conf Programmed Cell Death Regulation 2000, A95.
-
(2000)
Proc Am Ass Cancer Res Conf Programmed Cell Death Regulation
-
-
Jansen, B.1
Wacheck, V.2
Heere-Ress, E.3
Schlagbauer-Wadl, H.4
Hoeller, C.5
Trevor, L.6
Pratscher, B.7
Hoermann, M.8
Hollenstein, U.9
Eichler, H.10
Saunders, R.L.11
Fingert, H.12
Wolff, K.13
Pehamberger, H.14
-
63
-
-
0033397882
-
Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma
-
Grossman D, McNiff JM, Li F, Altieri DC: Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999;113:1076-1081.
-
(1999)
J Invest Dermatol
, vol.113
, pp. 1076-1081
-
-
Grossman, D.1
McNiff, J.M.2
Li, F.3
Altieri, D.C.4
-
64
-
-
0037440238
-
Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients
-
Gradilone A, Gazzaniga P, Ribuffo D, Scarpa S, Cigna E, Vasaturo F, Bottoni U, Innocenzi D, Calvieri S, Scuderi N, Frati L, Agliano AM: Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol 2003;21:306-312.
-
(2003)
J Clin Oncol
, vol.21
, pp. 306-312
-
-
Gradilone, A.1
Gazzaniga, P.2
Ribuffo, D.3
Scarpa, S.4
Cigna, E.5
Vasaturo, F.6
Bottoni, U.7
Innocenzi, D.8
Calvieri, S.9
Scuderi, N.10
Frati, L.11
Agliano, A.M.12
-
66
-
-
0035793557
-
Livin, a novel inhibitor of apoptosis protein family member
-
Kasof GM, Gomes BC: Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001;276:3238-3246.
-
(2001)
J Biol Chem
, vol.276
, pp. 3238-3246
-
-
Kasof, G.M.1
Gomes, B.C.2
-
67
-
-
0034597630
-
ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas
-
Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM: ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000;10:1359-1366.
-
(2000)
Curr Biol
, vol.10
, pp. 1359-1366
-
-
Vucic, D.1
Stennicke, H.R.2
Pisabarro, M.T.3
Salvesen, G.S.4
Dixit, V.M.5
-
68
-
-
0037452924
-
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction
-
Schmollinger JC, Vonderheide RH, Hoar KM, Maecker B, Schultze JL, Hodi FS, Soiffer RJ, Jung K, Kuroda MJ, Letvin NL, Greenfield EA, Mihm M, Kutok JL, Dranoff G: Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A 2003;100:3398-3403.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 3398-3403
-
-
Schmollinger, J.C.1
Vonderheide, R.H.2
Hoar, K.M.3
Maecker, B.4
Schultze, J.L.5
Hodi, F.S.6
Soiffer, R.J.7
Jung, K.8
Kuroda, M.J.9
Letvin, N.L.10
Greenfield, E.A.11
Mihm, M.12
Kutok, J.L.13
Dranoff, G.14
-
69
-
-
0034680876
-
Molecular determinants of the caspase-promoting activity of Smac/ DIABLO and its role in the death receptor pathway
-
Srinivasula SM, Datta P, Fan XJ, Fernandes-Alnemri T, Huang Z, Alnemri ES: Molecular determinants of the caspase-promoting activity of Smac/ DIABLO and its role in the death receptor pathway. J Biol Chem 2000;275:36152-36157.
-
(2000)
J Biol Chem
, vol.275
, pp. 36152-36157
-
-
Srinivasula, S.M.1
Datta, P.2
Fan, X.J.3
Fernandes-Alnemri, T.4
Huang, Z.5
Alnemri, E.S.6
-
70
-
-
0035843169
-
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
-
Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, OptizAraya X, McCombie R, Hermann JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-211.
-
(2001)
Nature
, vol.409
, pp. 207-211
-
-
Soengas, M.S.1
Capodieci, P.2
Polsky, D.3
Mora, J.4
Esteller, M.5
OptizAraya, X.6
McCombie, R.7
Hermann, J.G.8
Gerald, W.L.9
Lazebnik, Y.A.10
Cordon-Cardo, C.11
Lowe, S.W.12
-
71
-
-
0036803330
-
Effects of C(2)-ceramide on the Malme-3M melanoma cell line
-
Han W, Yoo J, Youn S, Kim D, Park K, Kim S, Kim K: Effects of C(2)-ceramide on the Malme-3M melanoma cell line. J Dermatol Sci 2002;30:10-19.
-
(2002)
J Dermatol Sci
, vol.30
, pp. 10-19
-
-
Han, W.1
Yoo, J.2
Youn, S.3
Kim, D.4
Park, K.5
Kim, S.6
Kim, K.7
-
72
-
-
0033811376
-
Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis
-
Sinha P, Kohl S, Fischer J, Hütter G, Kern M, Köttgen E, Dietel M, Lage H, Schölzer M, Schadendorf D: Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis 2000;21:3048-3057.
-
(2000)
Electrophoresis
, vol.21
, pp. 3048-3057
-
-
Sinha, P.1
Kohl, S.2
Fischer, J.3
Hütter, G.4
Kern, M.5
Köttgen, E.6
Dietel, M.7
Lage, H.8
Schölzer, M.9
Schadendorf, D.10
-
73
-
-
0012650752
-
Phase I trail of 17AAG (17-allylamino 17-demethoxygeldanmycine in patients with advanced cancer
-
Scher HI, Solit DB, Munster PN: Phase I trail of 17AAG (17-allylamino 17-demethoxygeldanmycine in patients with advanced cancer. Proc AARC-NCI-EORTC Int Conf 2001:A 292.
-
(2001)
Proc AARC-NCI-EORTC Int Conf
-
-
Scher, H.I.1
Solit, D.B.2
Munster, P.N.3
-
74
-
-
0037108860
-
Identification of the human PHLDA1/TDAG51 gene: Down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation
-
Neef R, Kuske MA, Prols E, Johnson JP: Identification of the human PHLDA1/TDAG51 gene: Down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. Cancer Res 2002;62:5920-5929.
-
(2002)
Cancer Res
, vol.62
, pp. 5920-5929
-
-
Neef, R.1
Kuske, M.A.2
Prols, E.3
Johnson, J.P.4
-
75
-
-
18344394549
-
Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes
-
Raisova M, Goltz G, Bektas M, Bielawska A, Riebeling C, Hossini AM, Eberle J, Hannun YA, Orfanos CE, Geilen CC: Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes. FEBS Lett 2002;516:47-52.
-
(2002)
FEBS Lett
, vol.516
, pp. 47-52
-
-
Raisova, M.1
Goltz, G.2
Bektas, M.3
Bielawska, A.4
Riebeling, C.5
Hossini, A.M.6
Eberle, J.7
Hannun, Y.A.8
Orfanos, C.E.9
Geilen, C.C.10
-
76
-
-
0033762077
-
Identification of differentially expressed genes in human melanoma cells with aquuired resistance to various antineoplastic drugs
-
Grottke C, Mantwill K, Dietel M, Schadendorf D, Lage H: Identification of differentially expressed genes in human melanoma cells with aquuired resistance to various antineoplastic drugs. Int J Cancer 2000;88:535-546.
-
(2000)
Int J Cancer
, vol.88
, pp. 535-546
-
-
Grottke, C.1
Mantwill, K.2
Dietel, M.3
Schadendorf, D.4
Lage, H.5
-
77
-
-
0037112453
-
Candidate genes for cross-resistance against DNA-damaging drugs
-
Wittig R, Nessling M, Will RD, Mollenhauer J, Salowsky R, Munstermann E, Schick M, Helmbach H, Gschwendt B, Korn B, Kioschis P, Lichter P, Schadendorf D, Poustka A: Candidate genes for cross-resistance against DNA-damaging drugs. Cancer Res 2002;62:6698-6705.
-
(2002)
Cancer Res
, vol.62
, pp. 6698-6705
-
-
Wittig, R.1
Nessling, M.2
Will, R.D.3
Mollenhauer, J.4
Salowsky, R.5
Munstermann, E.6
Schick, M.7
Helmbach, H.8
Gschwendt, B.9
Korn, B.10
Kioschis, P.11
Lichter, P.12
Schadendorf, D.13
Poustka, A.14
-
78
-
-
0013161392
-
Mechanisms of ras protein targeting in Mammalian cells
-
Silvius JR: Mechanisms of ras protein targeting in Mammalian cells. J Membr Biol 2002;190:83-92.
-
(2002)
J Membr Biol
, vol.190
, pp. 83-92
-
-
Silvius, J.R.1
|